What is Theolytics?
Theolytics operates at the intersection of virology, cancer biology, and immunology, specializing in the development of next-generation oncolytic immunotherapies. At the core of its operations is the ADENOVO discovery platform, a sophisticated technological framework designed to engineer viruses that selectively target and destroy solid tumors, with a primary focus on ovarian cancer. By integrating advanced molecular engineering with deep clinical insights, Theolytics aims to redefine the standard of care for patients facing difficult-to-treat malignancies. The company's market position is bolstered by its commitment to creating scalable, targeted therapies that address the significant unmet needs in the current oncology market, effectively bridging the gap between laboratory discovery and patient-centric clinical applications.
How much funding has Theolytics raised?
Theolytics has raised a total of $6.8M across 1 funding round:
Series A
$6.8M
Series A (2021): $6.8M with participation from Oxford Sciences Enterprises, Epidarex Capital, and TAIHO VENTURES , LLC
Key Investors in Theolytics
Oxford Sciences Enterprises
An independent investment firm that builds transformational businesses through a unique partnership with the University of Oxford.
Epidarex Capital
A transatlantic venture capital firm specializing in early-stage life science companies and precision medicine development.
TAIHO VENTURES, LLC
The corporate venture arm of Taiho Pharmaceutical, focusing on strategic investments in innovative oncology and immunology startups.
What's next for Theolytics?
With the recent capital injection, Theolytics is poised to transition its ADENOVO platform into more advanced stages of development. The strategic roadmap involves scaling its internal research capabilities and expanding its clinical trial infrastructure to validate the efficacy of its viral-based therapies. As the company moves forward, the focus will likely shift toward optimizing manufacturing processes and strengthening its intellectual property portfolio. This phase of growth is critical for establishing Theolytics as a leader in the immunotherapy sector, potentially attracting further interest from global biopharmaceutical partners looking to integrate innovative, virus-based oncology solutions into their existing pipelines.
See full Theolytics company page
